Kaposi Sarcoma Market Revenue, Growth Rate, And Applications By 2025
“Chemotherapy is likely to grow at the fastest pace during the forecast period due to the high cost of the treatment and the increasing adoption by immunocompentent patients.�
Kaposi Sarcoma is a tumor caused by infection with human herpes virus 8. It is also known as Kaposi sarcomaassociated herpes virus or KS agent. It becomes widely known as one of the AIDS-defining illnesses. It is viral infection. There is a widespread lack of awareness of this even among persons at risk for HHV-8 infection. Kaposi sarcoma (KS) is a systemic disease with cutaneous lesions with or without internal involvement. The Kaposi sarcoma (KS) is considered to be an AIDS-defining disease; indicating that patients with KS go on to develop AIDS. The incidence of Kaposi sarcoma was reportedly high in homosexual men with HIV. Kaposi Sarcoma is different from the other cancers in that lesions may be in more than one place in the body at the same time. These affected areas are called lesions. The skin lesions of KS most often appear on the legs or face and may cause it to swell painfully. KS can cause serious problems or even become life treating when the lesions are in the lungs, liver, or in digestive tract. The means that the when KS occurs in someone is infected with HIV. Chemotherapy, immunotherapy, and antiretroviral therapy (HAART) are the key treatment methods for Kaposi sarcoma. The HAART therapy emerged as the leading segment owing to the high incidence of AIDS-related Kaposi sarcoma globally. HAART therapy includes the combination of reverse transcriptase (RT) inhibitors, fusion inhibitors, and protease inhibitors. Chemotherapy is likely to grow at the fastest pace during the forecast period due to the high cost of the treatment and the increasing adoption by immunocompentent patients. Browse Full Research Report @ https://www.millioninsights.com/industry-reports/Kaposi-sarcoma-ks-market